Interim Management Statement

RNS Number:9853B
Celsis International PLC
14 August 2007

                            CELSIS INTERNATIONAL PLC

                    ("Celsis", "the Company" or "the Group")



                          Interim Management Statement



14 August 2007: Celsis International plc, the life sciences products and
laboratory services company, today provides its first Interim Management
Statement for the quarter ended 30 June 2007, as required by the UK Listing
Authority's Disclosure and Transparency Rules.



The Group has seen a strong start to the year and is in line with the Board's
expectations.  Each division of Celsis continues to perform well and core
markets in all of these areas remain robust.



The Analytical Services division, which provides outsourced laboratory testing
services, has seen a good first quarter across all segments of this business.
The order book remains strong and this division is well placed to continue to
deliver further solid revenue growth as the markets for our products and
services continue to expand.



The Rapid Detection division, which provides testing systems to more rapidly
detect microbial contamination, is building strength with instrument sales
increasing and reagent sales remaining strong.  Celsis anticipates that this
division's new nucleic acid-based testing systems will start to be tested by
customers as part of its product development activity by the calendar year end.



The integration of the In Vitro Technologies division (IVT), which helps
accelerate drug development by providing in vitro testing products and
development services, remains on track.  Celsis has seen solid growth from this
business during the first quarter of the year and is confident that this will
continue.  The IVT service business, Development Services, is now fully managed
by the Analytical Services division and focus in this area will be maintained to
maximise cross selling opportunities and synergies.



The Group's strong financial position has recently been helped by an accelerated
payment of $2.2 million in June 2007 which reduces Celsis' remaining bank loan,
from the acquisition of In Vitro Technologies, to $7.5 million.  Celsis will
continue to invest in its existing and new business areas as well as identifying
new opportunities beyond its current product and service offerings.



Overall, the Group has seen a very encouraging first quarter and the Board is
highly satisfied with the Company's progress to date and looks forward to a good
first half year.


Enquiries:

Celsis International plc                                      Tel: [phone]
Jay LeCoque, Chief Executive Officer
Jenny Parsons, Corporate Communications

Financial Dynamics                                            Tel: [phone]
Ben Atwell
David Yates





Notes to editors

Celsis International plc

Celsis International plc is a world leading provider of innovative life science
products and laboratory services to the pharmaceutical, biopharmaceutical, and
consumer products industries through its three business areas; rapid detection,
analytical and drug development services and ADME-Tox in vitro technologies.
The company is listed on the London Stock Exchange (CEL.L).



Each division of Celsis International plc has the capacity to deliver
substantial time and cost savings to its customers, in addition to ensuring
product quality and safety for consumers.  Using proprietary technology, the
Celsis Rapid Detection division provides diagnostic systems for the rapid
detection of contamination.  These systems provide significant economic value by
reducing the time it takes to test and release raw materials, in process and
finished goods to market.  Celsis Analytical Services division provides cost
effective outsourced laboratory testing services to pharmaceutical and
biopharmaceutical companies.  Its comprehensive service offerings include a full
spectrum of laboratory services from drug development and discovery to
analytical chemistry and biological sciences to stability storage and testing.
Celsis In Vitro Technologies (Celsis IVT) supplies in vitro testing products to
the pharmaceutical and biotechnology industries.  IVT's in vitro products screen
drug compounds early in the discovery process, thereby reducing the time and
cost of drug development.



Further information can be found on its website at www.celsis.com.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

IMSGUURARUPMGPW